投资者对诺沃·诺迪斯克提出的误导性增长索赔提起诉讼,造成销售前景下降21.8%的股票下跌。 Investors sued Novo Nordisk over misleading growth claims, causing a 21.8% stock drop after sales outlook was cut.

Novo Nordisk A/S(NVO)代表2025年5月7日至7月28日购买股票的投资者对Novo Nordisk A/S(NVO)提起了集体诉讼,指控该公司在竞争中就Wegovy和Ozempic的增长前景发表了误导性言论,并使GLP-1的使用复杂化。 A class action lawsuit has been filed against Novo Nordisk A/S (NVO) on behalf of investors who bought its stock between May 7 and July 28, 2025, alleging the company made misleading statements about its growth prospects for Wegovy and Ozempic amid competition and compounded GLP-1 use. 投诉称,诺沃·诺迪斯克公司低估了个人化例外在复合规则中的风险,并高估了病人转向其品牌药物的风险。 The complaint claims Novo Nordisk downplayed risks from a personalization exception in compounding rules and overestimated patient shifts to its branded drugs. 在该公司于2025年7月29日降低2025年的销售前景后,以增长放缓、竞争加剧和持续使用复合产品为借口,其股票在一天内下降了21.83%。 After the company lowered its 2025 sales outlook on July 29, 2025, citing slower growth, increased competition, and persistent compounded use, its stock dropped 21.83% in one day. 到2025年9月30日,在班级期间遭受损失的投资者可能有资格加入该案,由Pomerantz LLP、Levi & Korsinsky LLP和Frank R. Cruz律师事务所等公司处理诉讼事宜。 Investors who suffered losses during the class period may qualify to join the case by September 30, 2025, with firms like Pomerantz LLP, Levi & Korsinsky LLP, and The Law Offices of Frank R. Cruz handling the litigation. 参与是自愿的,不需费用。 Participation is voluntary and without cost.